Sartorius AG (XTER:SRT3) Forward PE Ratio

: 34.01 (As of Today)

View and export this data going back to 1990. Start your Free Trial

Sartorius AG's Forward PE Ratio for today is 34.01.

Sartorius AG's PE Ratio without NRI for today is 85.91.

Sartorius AG's PE Ratio for today is 85.91.

Sartorius AG Forward PE Ratio Historical Data

The historical data trend for Sartorius AG's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius AG Annual Data

Trend

2019-12

2020-12

2021-12

2022-12

2023-12

2024-04

Forward PE Ratio

53.19

64.10

59.88

34.72

42.92

40.82

Sartorius AG Quarterly Data
	2019-06	2019-09	2019-12	2020-03	2020-06	2020-09	2020-12	2021-03	2021-06	2021-09	2021-12	2022-03	2022-06	2022-09	2022-12	2023-03	2023-06	2023-09	2023-12	2024-03
Forward PE Ratio	59.17	48.31	53.19	58.48	82.64	77.52	64.10	62.11	60.98	58.48	59.88	40.98	36.23	33.56	34.72	40.16	53.19	39.68	42.92	52.91

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Sartorius AG's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sartorius AG Forward PE Ratio Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Sartorius AG's Forward PE Ratio falls into.

Sartorius AG Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Sartorius AG (XTER:SRT3) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Sartorius AG Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Sartorius AG's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Sartorius AG (XTER:SRT3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (XTER:SRT3) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

SOAGY:USA SSSGY:USA SUVPF:USA SARTF:USA 1SRT3:Italy SRT3d:UK 0NIR:UK SRT3:Austria

Address

Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079

Website

https://www.sartorius.com

Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.

Executives

Dr. Joachim Kreuzburg

Board of Directors

Sartorius AG (XTER:SRT3) Headlines

No Headlines